Sam68 promotes hepatic gluconeogenesis via CRTC2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34099657.
- Also identified by DOI 10.1038/s41467-021-23624-9 and PMC identifier 8185084.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Hepatic gluconeogenesis is essential for glucose homeostasis and also a therapeutic target for type 2 diabetes, but its mechanism is incompletely understood. Here, we report that Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis. Both global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. Protein, but not mRNA, levels of CRTC2, a crucial transcriptional regulator of gluconeogenesis, are >50% lower in Sam68-deficient hepatocytes than in wild-type hepatocytes. Sam68 interacts with CRTC2 and reduces CRTC2 ubiquitination. However, truncated mutants of Sam68 that lack the C- (Sam68<sup>ΔC</sup>) or N-terminal (Sam68<sup>ΔN</sup>) domains fails to bind CRTC2 or to stabilize CRTC2 protein, respectively, and transgenic Sam68<sup>ΔN</sup> mice recapitulate the blood-glucose and gluconeogenesis profile of Sam68-deficient mice. Hepatic Sam68 expression is also upregulated in patients with diabetes and in two diabetic mouse models, while hepatocyte-specific Sam68 deficiencies alleviate diabetic hyperglycemia and improves insulin sensitivity in mice. Thus, our results identify a role for Sam68 in hepatic gluconeogenesis, and Sam68 may represent a therapeutic target for diabetes.
Medical subject headings
- Adaptor Proteins, Signal Transducing
- Gluconeogenesis
- Liver
- RNA-Binding Proteins
- Transcription Factors